AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
2026-08-11 20:27
•Sara Appino •The Motley Fool
•••• •••• Axe Cap view
AbbVie vs CVS Health: Picking SA’s Healthcare Play for 2026
AbbVie’s focused drug growth outshines CVS’s turnaround but consider rand risks.
AbbVie’s rich pipeline, especially with Skyrizi and Rinvoq, sets it apart from CVS Health, whose diversified model and insurance arms provide steady cash but face pricing and regulatory pressures. On the JSE, direct healthcare biopharma exposure is limited, so USD/ZAR serves as a useful lens. A weaker rand would bolster Abbott’s dollar revenues when converted back, benefiting local investors in rand-hedged offshore funds. CVS’s South African read-through is less direct, but local insurers and healthcare providers could feel competitive pressure if integrated care models gain ground here. AbbVie’s 2.75% dividend yield adds income appeal amid uncertainty. A caution: AbbVie’s patent expirations and biosimilar competition remain risks if pipeline launches don’t sustain momentum. Still, given the global push for immunology and neuroscience treatments, AbbVie is better placed for growth than CVS’s slower path. this is just our opinion and not financial advice
Buy AbbVie via rand-hedged global funds to capture biopharma growth and a solid dividend. Avoid CVS stocks, which look fairly valued but face more headwinds and weaker SA linkage.
- ABBV
- USD/ZAR
- AbbVie pipeline setbacks or patent losses
- Rand strength eroding offshore returns
7/10
The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.
Our take is based on reporting first published by The Motley Fool.